Reducing drug related harms to health: an overview of the global evidence. by Hunt, Neil et al.
THE BECKLEY FOUNDATION
DRUG POLICY PROGRAMME
Neil Hunt, Mike Trace and Dave Bewley-Taylor
REDUCING DRUG RELATED
HARMS TO HEALTH:
AN OVERVIEW OF THE GLOBAL
EVIDENCE
R E P O R T   F O U R
Reducing drug related harms to health:
an overview of the global evidence
INTRODUCTION
This is the fourth report in our current series analysing the
effectiveness of drug policies in reducing drug use and related
problems. The first report articulated our concern that the
current international policy framework is not meeting its
objective of significantly reducing the scale of the illicit drug
market, and that the number of drug users is expanding in most
regions of the world. In our second report, we argued that the
way to resolve the consequent disagreements on the future
direction of policy should be through an objective review of the
effectiveness of current policies and programmes, and suggested a
broad methodology and approach for such a review to be
conducted. This report proposed six fundamental aims for drug
policies, the achievement of which could be measured over time
to judge whether progress was being made.
We have now moved on to consider the current global evidence
base for the effectiveness of specific policies and activities that are
designed to impact on drug-related problems. We started this
review in our third report, published in December 2004, which
assessed the impact of efforts to reduce the overall scale of drug
markets and drug use through supply reduction and law
enforcement programmes. Having found very little evidence that
these approaches can achieve significant and sustained reductions
in drug use, with this report we are starting to look at policies
and programmes that target specific drug-related harms, starting
with efforts to reduce the health damage associated with drug use
– primarily blood borne infections and overdose deaths.
This report, therefore, attempts to review the current evidence
for attempts to tackle these harms. Some of these activities –
needle and syringe programmes, low threshold access to
treatment and general health services for drug users – have
become known collectively as ‘Harm Reduction’.  The defining
feature of harm reduction programmes is their focus on the
prevention of drug-related harm rather than the prevention of
drug use itself. This is not to deny that, theoretically, a reduction
in use will lead to reduced harm; but it reflects a view that, while
they have laudable aspirations, policies primarily intended to
prevent drug use have rarely produced tangible results and have
proven unable to reduce the harms with which we are concerned.
However, as the Executive Director of the UN Office on Drugs
and Crime, Antonio Costa, has himself pointed out, all drug
policy activities aim to reduce harm. The crucial question is
which of these activities are effective in achieving that aim. We
need to understand whether the harms we are concerned about
are most effectively tackled by attempts to reduce overall levels of
use, by targeted action on the specific harmful behaviours, or by
a mixture of both approaches.
DRUG RELATED HARMS TO
HEALTH
Just as the effect of a drug is shaped by: its pharmacology and the
way it is administered; the person taking it; and, the immediate
and wider context in which it is consumed – drug, set and setting
as these are commonly termed (Zinberg 1984) - these same
factors directly affect the risk and harms of drug use.
Consequently, it is important to preface a discussion of harms by
underlining the fact that the risk of harm is not simply an
intrinsic property of any given substance but, instead, the
product of a constellation of factors. It is, in part, this insight that
has enabled the harm reduction perspective to generate an
expanding range of responses addressing these different factors
and progressively adding to the range of interventions at our
disposal.
Although many forms of harm are widely recognised,
international comparisons are not straightforward as harms are
often measured in different ways with considerable variations and
gaps in the quality of information. Even the USA, which spends
more on research than any other country, does not generate
national prevalence data on one of the most important problems
among injecting drug users (IDUs) – HIV infection - that can
readily be compared with other countries (Aceijas et al. 2004).
Despite useful progress in harmonising epidemiological data
across regions like the EU, data on other harms including
hepatitis, bacterial infection and overdose are even harder to
compare.
Blood-borne infections and overdose are, arguably, the most
widespread and serious causes of mortality and morbidity related
to drug use and are discussed in some detail below. However,
other forms of drug-related harm that are of note include:
‘addiction’/dependence or problem drug use (PDU) ; a wide range
of physical and mental health consequences; and, accidents
including those arising from drug driving.
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This review draws in part on an earlier review by Hunt et al. (2003)
The Beckley Foundation Drug Policy Programme (BFDPP) is a new initiative dedicated to providing a rigorous, independent
review of the effectiveness of national and international drug policies. The aim of this programme of research and analysis is to
assemble and disseminate material that supports the rational consideration of complex drug policy issues, and leads to a more
effective management of the widespread use of psychoactive substances in the future.
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HIV/AIDS
Although a number of people intuitively applied harm reduction
principles many years before the term was coined1 it was the
crisis of HIV/AIDS among injecting drug users that provided a
focus around which the range of responses most commonly
thought of as harm reduction could coalesce and develop.
Aceijas et al. (2004) have recently provided a global overview of
the linked epidemics of injecting drug use and HIV infection,
estimating prevalence for 130 countries.  Their work suggests that
there are 13.2 million injecting drug users  worldwide and that
“over ten million (78%) live in developing and transitional
countries (Eastern Europe and Central Asia, 3.1 million; South
and South-east Asia, 3.3 million; East-Asia and Pacific, 2.3
million). Estimates of HIV prevalence were available for 78
countries. HIV prevalence among IDUs of over 20% was
reported for at least one site in 25 countries and territories:
Belarus, Estonia, Kazakhstan, Russia, Ukraine, Italy,
Netherlands, Portugal, Serbia and Montenegro, Spain, Libya,
India, Indonesia, Malaysia, Myanmar, Nepal, Thailand, Viet
Nam, China, Argentina, Brazil, Uruguay, Puerto Rico, USA and
Canada.” These epidemics are substantially attributed to the
sharing of injecting equipment (UNAIDS 2003:68), with sexual
transmission also playing a significant role (Kral et al. 2001;
Strathdee et al. 2001).
Behind the global variations in HIV/AIDS prevalence among
IDUs, the epidemic is also spreading at differing rates.
Furthermore, national responses in line with best evidence are
currently implemented very unevenly. Although epidemic HIV/
AIDS has largely been averted or is now reversing in some
countries (e.g. Australia, Canada, Germany, Spain and the UK),
in many parts of the world it has followed - with near inevitably -
as injecting drug use has itself diffused across countries and,
indeed, entire regions. A previous briefing paper in this series
(Klein et al. 2004) has described the recent HIV pandemic across
two priority countries for action - Russia and Ukraine. Within
developing countries where injecting is prominent, six high
prevalence countries have recently been designated as having
‘generalized’ epidemics according to a UNAIDS/WHO
classification system (India, Myanmar, Thailand, Viet Nam,
Argentina and Brazil) with twice this number having
‘concentrated’ epidemics within particular sub-populations.
There are also indications that in Africa, where the epidemic has
largely been driven by sexual infection, one country – Libya -
may be at the early stage of a parallel epidemic driven by
injecting (Aceijas et al. 2003).
Hepatitis
Other than HIV, many other infections can be transmitted
through sharing injecting equipment. Hepatitis B (HBV) and
hepatitis C (HCV) are among the most important of these
because of their widespread prevalence and impact on health.
Globally, about 170 million people are estimated to have HCV
and in developed countries about 90% of people infected with
HCV are former or current injecting drug users (WHO 2000).
With few exceptions, studies of current IDUs find that HCV
prevalence exceeds 50% with several countries finding that
almost all IDUs are infected (for example see Jager et al.
2004:96).
Hepatitis B prevalence is generally lower although, unlike HCV,
HBV is readily spread through sexual contact. People with HBV
are also at risk of co-infection with hepatitis D, which cannot be
acquired independently. In general, co-infection with different
viruses and re-infection with different strains or sub-types of the
same virus worsen the prognosis and risks of chronic hepatitis,
cirrhosis and liver cancer. Outbreaks of hepatitis A - generally
transmitted through the oro-faecal route rather than as a blood-
borne infection – are also rising in some populations of IDUs
(Health Protection Agency 2004).
It is now known that HCV, which is much more readily
transmitted by needle-sharing than HIV, was endemic among
IDUs in many countries with longer histories of injecting before
either tests for it became available or harm reduction services
were introduced. Although there are some indications that
programmes may bring about local, short-term reductions in its
prevalence, it is currently unclear whether there are policies that
can bring about effective and sustained reductions. HCV
infection continues to follow the same pattern of spread in later
epidemics of injecting. To date there are no examples of countries
that have introduced comprehensive harm reduction
interventions prior to its spread across large numbers of IDUs
and, the important question of whether such an approach could
effectively prevent its spread is currently unanswered. By
contrast, the existence of an effective immunisation for HBV
points to a simple intervention that can readily prevent the spread
of this infection among IDUs within countries that choose to
implement targeted or population-wide vaccination programmes.
Local and systemic bacterial infections
Besides blood-borne viruses such as HIV, HBV and HCV,
bacterial infections are also common among injecting drug users
due to poor injecting hygiene or the use of contaminated drugs.
Clinically, infections giving rise to abscesses, cellulitis,
endocarditis and septicaemia are often encountered. Numerous
pathogens can affect people who inject including: staphylococcus
aureus, of which Methicillin Resistant Staphylococcus Aureus
(MRSA) is an important example; streptococcal infections; and,
clostridial infections such as botulism, tetanus and clostridium
novyii. As yet, national monitoring systems for bacterial
infections among IDUs are, however, in their infancy where they
exist at all.
Overdose
Among young adults, ‘overdose’2 associated with opioids is one
of the leading causes of premature death associated with drug use.
Within industrialised countries, rates have generally been rising
through the 1980s, 1990s and into the early 21st century. During
2000, more than five times as many IDUs died of overdose
within Europe as those who died of AIDS. Furthermore,
overdose deaths contribute a disproportionately high rate of
‘years-of-life-lost’ because they largely arise among younger
adults. So, for example, it has been calculated that during 1997
drug-related deaths caused a similar number of years of life lost
as traffic accidents within the UK and accounted for 5% of all
male years of life lost (ACMD 2000: 56). In 1995 it has been
estimated that among 15-35 year old males, overdose contributed
15% of all deaths in Munich and 17% in Barcelona and, a third of
male deaths in Glasgow were attributed to overdose in 2003
(Hedrich and Vicente 2004).
3
1 Among them Sir Humphrey Rolleston whose 1926 report on morphine and
heroin addiction led to the introduction of the ‘British System’ of heroin control.
And, most presciently, Jan Howard and Philip Borges who investigated needle
sharing in connection with the spread of hepatitis B among San Francisco
injecting drug users more than 30 years ago (Howard and Borges 1971).
2 In recent years it has become clearer that overdoses do not typically arise from
unusually high purity heroin taken in isolation. Often, ‘heroin overdose’ occurs with
amounts that would not generally be lethal but become so when heroin is potentiated
by other depressants such as alcohol or benzodiazepines (Darke and Zador 1996).
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The World Health Organisation (WHO 1998a) has drawn
attention to the considerable limitations to our existing
information: problems that are almost certainly greater in
developing and transitional countries where health information
systems are poorer and ‘overdose’ may be confounded with the
consequences of infectious diseases and malnutrition. In some
countries, overdose data are reported within other data on
poisonings, deliberate and accidental deaths and can be hard to
distinguish from other causes of death.
Although they generally contribute fewer cases than the opioids,
the use of cocaine, ecstasy, methamphetamine and other
amphetamine-type-stimulants can each also precipitate life-
threatening, and sometimes fatal, emergencies.
Within the European Union, death rates more than doubled
between 1985 and 2000. Each year the figure is between 8-9,000
fatal overdoses – a figure that is very much thought to
underestimate the true rate (EMCDDA 2004:12). In 1999, 958
deaths in Australia were attributed to opioid overdose and it was
estimated that between 12,000 – 21,000 non-fatal overdoses were
occurring in Australia every year (Ministerial Council on Drug
Strategy 2001): a rate that has since declined markedly (see
Beckley Foundation briefing paper No. 4). Within Canadian
national data, 160 deaths were attributed to opiate poisoning and
a further 78 to cocaine during 1995 (Single et al. 2000). In the
USA the absolute number of ‘drug-induced deaths’ has increased
from 19,102 in 1999 to 26,018 in 2002; an increase in mortality
rate from 6.8 to 9.0 per 100,000 (CDC 2004:11)3. Again, however,
US surveillance has disappointingly limited comparability with
other countries as opioid-related deaths are not disaggregated
from poisonings with prescribed drugs.
INTERVENTIONS AND THEIR
EFFECTIVENESS
This section summarises the background, evidence and extent of
implementation for interventions relating to the main harms
identified above. In practice, these are often interlinked (for
example needle and syringe programmes (NSPs) and outreach);
however, for ease of discussion they are treated separately under
the following headings: needle and syringe programmes;
methadone and other replacement therapies; heroin prescribing;
information, outreach and motivational enhancement;
interventions to reduce overdose and poisonings; and, drug
consumption rooms.
Needle and syringe programmes (NSPs)
Background
The role of ‘needle sharing’ in the transmission of blood-borne
viral infections such as hepatitis B among injecting drug users
(IDUs) has been known since at least the 1970s (Howard and
Borges 1971). However, it was the spread of HIV/AIDS within
populations of injecting drug users in the 1980s that prompted
the widespread introduction of needle and syringe programmes
(NSPs) within a number of industrialised countries across
Europe, Oceania, parts of North America (Gibson et al. 2001)
and, more latterly, within a number of developing and
transitional countries (Ball et al. 1998; Bastos et al. 2000;
Commonwealth Department of Health and Ageing 2002).
People inject for a variety of reasons, among which are the added
intensity of the initial sensation  - the ‘rush’ - and the way that
injecting maximises the availability of the drug to the brain,
which can make injecting more economical. Although sharing
needles and syringes is the main way that blood-borne infections
are transmitted between IDUs, sharing other injecting
paraphernalia – cookers, filters and water for injecting – and
practices by which drugs are divided – backloading and
frontloading – all increase risk. ‘Sharing’ can also transmit less
well known blood-borne viruses such as HTLV-1 and HTLV-2 as
well as viral infections (e.g. hepatitis A) and many bacterial
infections that are more often transmitted by other routes (e.g.
tetanus). Although we primarily think about HIV/AIDS and
hepatitis, needle sharing remains an important potential route of
transmission for new, currently-unknown infections posing
unquantifiable risks within humans that may be acquired from
animals; as seems likely to have happened when an adapted
version of Simian Immunodeficiency Virus (SIV) crossed from
apes to humans and produced HIV.
NSPs primarily work by enabling IDUs to avoid sharing and, in
this way, prevent the spread of disease. This helps sustain the
health of IDUs and reduce the associated costs to society. It also
means that those people who eventually stop injecting are less
likely to have long term residual health consequences from their
drug use or, comprise an ongoing risk of transmitting acquired
diseases sexually.
Regulations or law enforcement restricting the availability of
needles and syringes mean that people who inject are much more
likely to share. Even where sterile needles and syringes are
available for sale through pharmacies or other retail outlets, their
cost and the desire for anonymity can prevent IDUs from using
them. Consequently, NSPs provide free, accessible sterile needles
and syringes to reduce the need for sharing and re-use. They also
enhance public health by removing used equipment from
circulation.
Programmes operate in different ways including specialist
services linked to treatment agencies, pharmacy exchange,
outreach and with the use of vending machines. Specialist services
usually fulfil a range of further health promotion and primary
healthcare functions and often provide access to other treatment
services that help people address problem drug use, for example
by providing testing for HIV and hepatitis, vaccination against
HBV, overdose prevention and management training and, referral
to opioid maintenance, detoxification or counselling services.
Clinical and cost effectiveness
Since the 1980s, there have been many investigations concerning
the impact of NSPs on risk behaviours and the viral status of
people who use them.
A systematic review by Gibson et al. (2001) investigated the
question – “Are needle and syringe programmes effective at
reducing HIV risk behaviours and HIV infection among injecting
drug users?” Of 42 studies, 28 found positive effects and 14
found either no association or a combination of positive and
negative effects. They concluded that this gives extremely strong
evidence of the positive impact of NSPs on HIV risk behaviour
and HIV infection and good justification for their
implementation.
3 Includes poisonings from medically prescribed drugs. The Centers for Disease
Control and Prevention do not disaggregate deaths from prohibited drugs so it
unclear what fraction of these deaths are associated with heroin or cocaine.
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More recently, the World Health Organisation commissioned a
review of 200 studies relating to NSPs, which concluded that:
• There is compelling evidence that increasing the
availability and utilization of sterile injecting equipment
by IDUs reduces HIV infection substantially.
• There is no convincing evidence of any major, unintended
negative consequences.
• Needle syringe programmes are cost-effective.
• Needle syringe programmes have additional and
worthwhile benefits apart from reducing HIV infection
among IDUs.
• Bleach and other forms of disinfection are not supported
by good evidence of effectiveness for reducing HIV
infection.
• Pharmacies and vending machines increase the
availability and probably of the utilization of sterile
injecting equipment by IDUs.
• Injecting paraphernalia legislation is a barrier to effective
HIV control among IDUs.
• Needle syringe programmes on their own are not enough
to control HIV infection among IDUs.
WHO. Effectiveness of sterile needle and syringe
programming in reducing HIV/AIDS among injecting
drug users. Geneva: WHO. 2004a: Pages 28-29
In the face of a burgeoning global literature on ‘what works’, one
valuable function of international bodies is to distil out the most
important messages for policy makers. Recently, the World
Health Organisation, UNAIDS and United Nations Office on
Drugs and Crime considered the policy and programming
implications of the WHO review concerning the provision of
sterile injecting equipment and HIV transmission and collectively
drew the following conclusions:
Communities or countries threatened by or experiencing an
epidemic of HIV infection among injecting drug users should
urgently adopt measures to increase the availability and
utilization of sterile injecting equipment and to dispose of used
equipment. They should provide risk-reduction education,
referrals to drug-dependence treatment and abscess management,
promote condom use, HIV testing and counselling, and provide
care, treatment and support for persons with HIV/AIDS and
treatment of sexually transmitted infections. If necessary,
legislation related to drug dependence and drug paraphernalia
should be reviewed and amended in order to allow for and
promote the implementation of needle and syringe programmes.
Programmes should be implemented on a large enough scale to
stop and reverse HIV/AIDS epidemics among injecting drug
users. Pilot programmes may have a place in allowing the
introduction of such programmes and testing different delivery
mechanisms in different contexts. However, the international
experience across countries and regions is so convincing that there
is no longer any real justification for such small-scale programmes.
Pilot programmes may further delay the much-needed expansion
phase and result in inadequate coverage. However, the exact
modalities of needle and syringe programmes as well as service
delivery options have to be adapted to specific local circumstances.
Programmes aimed at providing sterile injecting equipment
should be specifically designed to meet the needs of subpopulations
of injecting drug users, e.g. women, inmates of prisons, male or
female sex workers and ethnic minorities. Inmates of correctional
facilities are at particularly high risk for HIV infection as they
often continue to inject drugs while incarcerated.
There is only limited evidence supporting the effectiveness of
disinfection and decontamination schemes. They should only be
advocated as temporary measures where it is not feasible to
implement programmes for the provision of sterile injecting
equipment
WHO, UNAIDS, UNODC (2004a) Policy Brief: provision of
sterile injecting equipment to reduce HIV transmission.
Prisons
Relative to the general population prisoners have much higher
lifetime levels of drug use and injecting and their risk exposure
can be greatly increased. Programmes distributing and promoting
the use of bleach are one way by which people have sought to
reduce these risks (Dolan et al. 1999). However, in recent years,
NSPs within prisons in Europe have increasingly been developed,
with 46 such programmes identified by 2003 (Stover and Nelles
2003). Evaluations have documented reductions in sharing rates,
no new acquisitions of HIV, HBV or HCV and no serious
unintended consequences (Dolan et al. 2003).
Following a recent review of the evidence concerning NSPs in
prisons the WHO, UNAIDS and UNODC (2004b) concluded:
The evidence shows that such programmes should include all the
measures against HIV transmission which are carried out in the
community outside prisons, including HIV/AIDS education,
testing and counselling performed on a voluntary basis, the
distribution of clean needles, syringes and condoms, and drug-
dependence treatment, including substitution treatment. All these
interventions have proved effective in reducing the risk of HIV
transmission in prisons. They have also been shown to have no
unintended negative consequences.
In a review written with particular reference to eastern Europe
and the Russian Federation, the World Health Organisation
suggest that programmes are best introduced experimentally and
evaluated during their initial implementation (WHO 2001: 60-
61). Uniquely, Spain has adopted a national approach as part of
its rapid scaling up of harm reduction interventions and has
decreed that all of its prisons should provide needle exchange; the
results of this approach will be important to review.
NSPs as a point of early access to drug treatment
Although HIV prevention was the original aim of NSPs and may
be regarded as their primary outcome, NSPs also provide an
important route into structured treatment for people who would
otherwise be regarded as ‘hard-to-reach’. This accelerated access
to treatment can reduce the wider spectrum of risks
accompanying injecting. Among the studies that have examined
treatment uptake it is evident that NSPs do indeed fulfil this role
(Normand et al. 1995; Heimer et al. 1996); with one British study
finding that as many as 40% of 722 visitors acted on referrals to
external help (Carvell et al. 1990). Research in Puerto Rico has
also emphasised the value of proactive approaches to referral
(Robles et al. 1998).
What impact do NSPs have on hepatitis C?
Most evaluation has focused on HIV. However, HCV is far more
prevalent than HIV among IDUs.  Evidence of beneficial impacts
of NSPs on HCV has been slower to emerge as, by the time NSPs
were introduced, HCV was virtually endemic among injecting
drug users and is more easily transmitted. So, rather than averting
an epidemic, in most populations the task has been to reverse
one. Initially, it seemed uncertain whether NSPs could have any
impact on HCV prevalence as the evidence suggested that
measures which are adequate to avert HIV are not necessarily
sufficient for hepatitis C. However, there are now some early
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indications that, from a generally high baseline, NSPs may be
having an impact; even though HCV incidence rate and levels of
viraemia remains unacceptably high (Smyth et al. 1999; Taylor et
al. 2000; Commonwealth Dept of Health and Ageing 2002;
Parsons et al. 2002). There is also some limited evidence that
NSPs may provide opportunities to prevent people beginning to
inject (Hunt et al. 1998).
One of the key conclusions from a further review of NSPs with
particular reference to HCV is that services may need to be far
more proactive than has been necessary for HIV if they are to be
effective at preventing HCV (Ashton 2004). In recent years, there
has also been growing recognition of the importance of achieving
adequate coverage i.e. NSP provision that enables people to use
one sterile needle and syringe for each injection. This may be
especially important for effective HCV prevention. Parsons et al.
(2002) identified a contrast between relatively low NSP coverage
and higher HCV prevalence in Scotland, with correspondingly
higher coverage in England and lower HCV prevalence. Wiessing
et al. (2001) have identified substantial variation in NSP coverage
across Western Europe with estimates that vary between 0.4
distribution points per 100,000 IDUs (Belgium) to between 12-22
distribution points per 100,000 IDUs in Spain.
Finally, turning to cost-effectiveness, several studies have used a
range of different methodologies to quantify the costs and cost
effectiveness of NSPs (Gold et al. 1997; Lurie and Drucker 1997;
Holtgrave et al. 1998; Laufner 2001). In each case NSPs were
shown to be cost effective. An independent national review in
New Zealand has calculated that each $NZ spent on NSPs yields
a $NZ20 saving in lifetime treatment costs (The Centre for Harm
Reduction 2002). Taking the most conservative estimate from an
Australian study suggests that the investment in NSPs for one
year saves over A$2 billion in direct HIV and HCV treatment
costs alone: a figure that does not include the additional gains in
Quality Adjusted Life Years for people who avoid infection. The
investigators conclude that “NSPs are effective in reducing the
incidence of both diseases and that they represent an effective
financial investment by government” (Commonwealth Dept of
Health and Ageing 2002).
Adoption and implementation
History shows that, within countries where injecting occurs, the
early adoption of NSPs can avert epidemic spread of HIV/AIDS
(Stimson 1996).  In 1999, Strathdee and Vlahov (2001) identified
134 countries, regions or territories where injecting is
documented, of which 114 (84%) reported HIV among IDUs.
Using the highly conservative measure of countries that have
introduced at least one NSP, they note that only 40% of countries
in which injecting occurs have introduced a NSP: this was the
case for only a third of countries in which HIV has been reported
among IDUs. The proportion of countries that achieve accessible
NSP coverage for all of the eligible population would be
substantially smaller.
As has been noted, in their more recent global overview of
injecting and HIV across 130 countries, Aceijas et al. (2004)
estimate that there are 13.2 million injecting drug users (IDU)
worldwide and that over ten million (78%) live in developing and
transitional countries. With the obvious exception of the USA,
where a Congressional ban prevents the use of federal funds for
NSPs, provision is relatively good in many industrialised
countries; albeit with considerable variations in coverage
(Wiessing et al. 2001). However, despite important developments
in provision within countries such as India, Brazil, Russia, China
and Viet-Nam, in most developing and transitional countries
NSP programmes are the exception rather than the rule
(Strathdee and Bastos 2003; Hammett et al. 2003). Nevertheless,
Brazil provides a striking example of a country that has
introduced extensive needle and syringe provision despite having
high levels of poverty (Transnational Institute 2004: 20-21).
Summary
There is substantial evidence that NSPs are effective at preventing
HIV and reducing risk behaviours that can transmit this and
other blood-borne viruses such as hepatitis B and C. NSPs are a
cost effective intervention for preventing HIV. Their eventual
capacity to produce outcomes in other areas - notably reducing
overdose deaths and preventing hepatitis C - is less certain and
warrants urgent attention. There are some evident opportunities
to improve existing practice with regard to both the intensity of
services and coverage.
Methadone and other
replacement therapies
Background
Methadone is the most widely used and researched opioid4
replacement therapy  (Hall et al. 1998:1-2). Hall et al. describe
opioid replacement therapy as a form of treatment that:
…involves the administration of a long-acting opioid drug to an
opioid dependent person, usually by a non-parenteral route of
administration, for the therapeutic purposes of preventing or
substantially reducing the injection of illicit opioids, such as heroin.
Its goal is to improve the health status and psychological and
social well-being of the opiate-dependent person.
The use of methadone was pioneered by Dole and Nyswander
(1965, 1967) because it prevents withdrawal symptoms, does not
produce the characteristic, euphoric ‘high’ of heroin and has a
long action (24-36 hours) and, therefore, only requires daily
administration. These features enable people with opioid
dependence to participate in rehabilitation programmes. Its
beneficial effect on both heroin use and crime led to its rapid
adoption across the USA and beyond, and has been further
stimulated by indications of its potential importance as a
component within the global response to HIV/AIDS among
people who inject drugs.
The aims of substitution treatment can be summarised as being
to:
• Assist the patient to remain healthy, until, with the
appropriate care and support, they can achieve a life free
of illegal drugs;
• Reduce the use of illicit or non-prescribed drugs by the
individual;
• Deal with problems related to drug misuse;
• Reduce the dangers associated with drug misuse,
particularly the risk of death by overdose and of HIV,
hepatitis B & C, and other blood-borne infections from
injecting and sharing injecting paraphernalia;
• Reduce the duration of episodes of drug misuse;
• Reduce the chances of future relapse to drug misuse;
• Reduce the need for criminal activity to finance drug
misuse;
• Stabilise the patient where appropriate on a substitute
medication to alleviate withdrawal symptoms;
• Improve participation in other medical care; and,
• Improve overall personal, social and family functioning.
4 Opioid is the collective term for all ‘opiates’ (drugs derived from the opium
poppy) but also includes synthetic narcotic analgesics (such as methadone) that
exert a similar effect to the opiates.
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Increasingly, evidence also supports the use of the mixed opiate
agonist/antagonist – buprenorphine – for maintenance. Several
other treatments are sometimes used including the long acting
opioid LAAM, dihydrocodeine, tincture of opium and various
slow release formulations of morphine. Additionally,
amphetamine prescribing has occasionally been undertaken with
stimulant users. However, with the exception of buprenorphine,
the evidence for all of these other treatments is weak at present
and, in the case of LAAM, there are concerns about cardiac side
effects.
Clinical and cost effectiveness
Methadone has been in use for approaching 40 years and its
efficacy has been investigated extensively. Several reviews have
systematically examined the evidence to evaluate the conclusions
that can reasonably be drawn. These include two major academic
textbooks (Ball and Ross 1991; Ward et al. 1998), two reports
from authoritative bodies (Gerstein and Harwood 1990; ACMD
1993) and two reviews published in peer-reviewed journals
(Farrell et al. 1994; Marsch 1998). All of these conclude that
methadone treatment is beneficial and effective. The emphasis
and focus within each review varies, with later studies widening
their focus to include HIV prevention. Methadone maintenance
treatment emerges as a treatment that is effective at reducing
heroin use, crime and HIV risk behaviours.
Beyond the evidence from the reviews above, a Cochrane review5
(Mattick et al. 2003a) has assessed methadone maintenance. The
review confirmed that methadone maintenance treatment is an
effective intervention for the management of heroin dependence,
that methadone is superior to the drug-free alternatives (placebo
medication, offer of drug-free treatment, detoxification, or
waiting-list control) for retaining patients in treatment and that it
reduces heroin use. The authors conclude that “methadone
should be supported as a maintenance treatment for heroin
dependence”.
Several specific factors have been examined for their effect on
outcomes and are also useful to consider:
• Dose6 is consistently related to retention and illicit
opioid use, with low dose predictive of drop out;
• By contrast, programmes that enforce withdrawal from
methadone appear to be ineffective; and,
• The amount and quality of support services affects
treatment outcome, with higher support and better
quality services enhancing outcome, but diminishing
returns with very high intensity.
This suggests that caution is advisable where any divergence is
contemplated from Dole and Nyswander’s (1967) original
programme, which was based on a relatively high average dose
and well resourced psychotherapeutic and rehabilitative services.
In this regard, Ashton and Witton (2004) have usefully drawn
attention to the importance of aspects of programme delivery that
seem pedestrian but have an important impact on uptake and
retention notably “treating the patient as an individual, being
welcoming, empathic, under- standing, and demonstrating respect
and active, persistent caring”.
Spain provides an interesting example of a country that has
introduced policies which appear to be reversing a serious
epidemic. Spain’s policy was based on abstinence until the early
1990s when it had the highest rate of HIV infection among IDUs
in Europe (Rinken and Romero-Vallecillos 2002). The
introduction of a rapidly expanded programme of methadone
treatment from 1992-1994 has since seen marked reductions in
HIV (Hernandez-Aguado et al., 1999). Rinken and Romero-
Vallecillos comment on the parallels with parts of Central and
Eastern Europe, notably Ukraine.
Prisons
Although there is less research on opioid replacement therapy
within prisons, what evidence there is suggests that drug use and
injecting risk behaviours are both reduced  (Dolan et al 1998;
Vegue-Gonzalez et al. 1998). The WHO/UNODC and
UNAIDS (2004:6) identify the high rates of opioid dependence
among prisoners and the WHO describes opioid substitution
treatment as a requirement for successful HIV prevention in
prisons (WHO 2004b). An extensive review of good practice
written with particular reference to Eastern Europe and the
Russian Federation (WHO 2001) draws attention to earlier
WHO guidance, which states that:
Prisoners on methadone maintenance prior to imprisonment
should be able to continue this treatment while in prison. In
countries in which methadone maintenance is available to opiate-
dependent individuals in the community, this treatment should
also be available in prisons.
The arguments for providing such treatment and the concerns
and criticisms have been further examined by Dolan et al. (1998)
who conclude that they should confer broadly similar benefits.
However, they also argue that there is a need for well-designed,
prospective, randomised controlled trials to better clarify their
impact.
Recently, the World Health Organisation, United Nations Office
on Drugs and Crime and UNAIDS (2004c) have reviewed the
evidence concerning substitution therapy and issued a joint
position paper oriented towards policy makers. The conclusions
from any collaboration of international bodies of this sort are of
particular note and the joint statement is therefore reproduced
below:
Joint position paper on ‘Substitution maintenance therapy in
the management of opioid dependence and HIV/AIDS
prevention’
Opioid dependence, a complex health condition that often
requires long-term treatment and care, is associated with a high
risk of HIV infection when opioids are injected using
contaminated injection equipment. Drug dependence treatment
is an important strategy to improve well-being and social
functioning of people with opioid dependence and to reduce its
health and social consequences, including HIV infection. As no
single treatment is effective for all individuals with opioid
dependence, sufficiently diverse treatment options should be
available. Substitution maintenance therapy is one of the most
effective treatment options for opioid dependence. It can decrease
the high cost of opioid dependence to individuals, their families
and society at large by reducing heroin use, associated deaths,
HIV risk behaviours and criminal activity. Substitution
maintenance therapy is a critical component of community-based
approaches in the management of opioid dependence and the
prevention of HIV infection among injecting drug users (IDUs).6 For an extended analysis and discussion of the issues concerning dosing and
patient self-regulation see Ashton (2002).
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5 The Cochrane Library is an international scientific collaboration that uses meta-
analytic procedures to combine comparable findings from different randomised
controlled trials. The rigour and robustness of this approach means that it is often
regarded as a ‘gold standard’.
Provision of substitution maintenance therapy – guided by
research evidence and supported by adequate evaluation, training
and accreditation – should be considered as an important
treatment option in communities with a high prevalence of opioid
dependence, particularly those in which opioid injection places
IDUs at risk of transmission of HIV and other bloodborne
viruses.
WHO, UNODC, UNAIDS (2004c)
Summarising the evidence on cost effectiveness, the WHO/
UNODC and UNAIDS (2004c: 21) also conclude that:
Opioid dependence treatment is effective in reducing illicit opioid
use and its associated health and social costs. Treatment is
considerably less expensive than alternatives, such as not treating
people with opioid dependence, or imprisonment.
According to several conservative estimates, every dollar invested
in opioid dependence treatment programmes may yield a return
of between $4 and $7 in reduced drug-related crime, criminal
justice costs and theft alone. When savings related to health care
are included, total savings can exceed costs by a ratio of 12:1.
There is scientific evidence that substitution maintenance therapy
is a cost-effective treatment modality with cost–effectiveness
measures comparing favourably with other health care
interventions, such as medical therapy for severe hypertension or
for HIV/AIDS.
WHO, UNODC, UNAIDS (2004c)
Buprenorphine
Increasingly, the mixed opioid agonist/antagonist
buprenorphine is also being used within opioid
replacement therapy. Three systematic reviews of its
effectiveness have been undertaken including one by
Mattick and colleagues within the Cochrane Library (West
et al. 2000; Barnett et al. 2001; Mattick et al. 2003b). The
evidence suggests that buprenorphine may usefully
complement methadone, especially where people may be
moving towards a reduction in use and the WHO/
UNODC/UNAIDS position paper (2004c) summarises the
main conclusions that can be drawn:
Buprenorphine is acceptable to heroin users, has few side-
effects, and is associated with a relatively mild withdrawal
syndrome. When used in opioid substitution therapy for
pregnant women with opioid dependence, it appears to be
associated with a lower incidence of neonatal withdrawal
syndrome.
Adoption and implementation
In keeping with the extensive evidence of its effectiveness, an
increasing number of countries now provide methadone
treatment within opioid substitution programmes. Although used
less extensively, buprenorphine is also progressively becoming
available.
Methadone is available in almost every state across the USA, in
Canada and is also used in South America. In October 2002
buprenorphine was licensed for use within the USA7.
Within the European Union, methadone treatment is widely
available in the 15 ‘old’ member states; with 400,000 people
receiving treatment. However, it is provided less consistently
within the 10 new states (EMCDDA 2004). Buprenorphine has
been licensed for use within a growing number of countries since
1996 and is now available as a substitute treatment in all of the
‘old’ states except the Netherlands and Ireland, where it is only
used for detoxification.
In 2002, a review of pharmacotherapy within South-East Asia
and the Western Pacific identified ‘formal’ opioid maintenance
programmes within Hong Kong SAR, Nepal and Thailand
(WHO 2002). More recently, China has begun an ambitious
programme to develop and scale up methadone treatment and has
also begun trials of buprenorphine (Thompson 2004).
A World Health Organisation review of pharmacotherapy for
opioid dependence in Central and Eastern Europe found that
substitution treatment – primarily with methadone – exists in all
countries across the region with the exceptions of Russia and
Belarus (WHO 2004c). However, coverage is uneven and in some
states such as Ukraine and Kyrgyzstan provision is still occurring
within pilot programmes. In Belarus, methadone treatment is
legally possible but the Russia Federation currently prohibits the
use of methadone and buprenorphine.
Since 2002, WHO, prompted by an earlier recommendation from
the INCB, has been reviewing the international control of
buprenorphine with a view to rescheduling the drug from the
1971 Convention on Psychotropic Substances to the 1961 Single
Convention on Narcotic Drugs.  More stringent control of
buprenorphine under the Single Convention may impact its
availability for opioid replacement therapy (Framer and Wodak,
manuscript in preparation; Silva 2004).
Summary
Methadone maintenance treatment is the most researched
treatment currently available for people who are dependent on
opioids. Its use is supported by an evidence-base developed over
almost 40 years and from across many different countries. It
retains patients in treatment for longer than any alternative, non-
replacement therapy, and has a superior effect on the reduction of
heroin use and crime associated with opioid dependence. It is
effective at reducing HIV risk behaviours and there is evidence
that it also reduces the risk of mortality from opioid use.
Increasingly, buprenorphine is used and appears to have merit as
a second line treatment. It may offer benefits under certain
circumstances, but methadone treatment prescribed at an
adequate dose and with suitable psychotherapeutic and social
support is currently the first treatment that should be considered
and the most effective.
It is of note that, at the time of the preparation of this review,
methadone (WHO 2004d) and buprenorphine (WHO 2004e) are
both being considered for addition to the WHO list of Essential
Medicines: the most important “safe, effective treatments for the
infectious and chronic diseases which affect the vast majority of
the world’s population”.
Heroin prescribing
Background
As has been noted, the most common substitution drug for
heroin is methadone. However, despite the benefits of oral
methadone that have been documented , there are people who do
not want it or benefit from it. They are not attracted into drug
treatment or, if receiving treatment, do not significantly change
their behaviours.
7 US Medicine, November 2002. http://www.usmedicine.com/
article.cfm?articleID=537&issueID=44 Accessed 24/2/03
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The UK is exceptional because heroin has been prescribed to
treat addicts since the 1920s within what is often referred to as
‘The British System’. It was originally adopted to help addicted
people lead normal lives. The heroin is usually prescribed in an
injectable form but has also been prescribed within smokable
‘reefers’. More recently the British government has proposed a
limited expansion of heroin prescribing because of its potential
impact on reducing crime as well as improving the health of
patients. About 450 patients get heroin on prescription from
some 46 licensed doctors (Metrebian et al. 2002).
Clinical trials in Switzerland and the Netherlands have used a
combination of injectable and smokable preparations in
conjunction with methadone. Switzerland has now authorised the
prescription of heroin for opiate dependence. Since 1998, heroin
can be prescribed in the Netherlands for research purposes. In
the Swiss and Dutch trials heroin was dispensed and
consumption supervised at the clinic as part of research studies.
Clinical and cost-effectiveness
The evidence base for the effectiveness of heroin as a treatment
drives from  four small-scale studies in the UK (Hartnoll et al.
1980; Stimson and Oppenheimer 1982; McCusker and Davies
1996; Metrebian et al. 1998), one large trial with multiple
components undertaken in Switzerland and two large trials
conducted in the Netherlands. There have been four randomised
controlled trials – one in the UK (Hartnoll et al. 1980), one in
Switzerland (Perneger et al. 1998), and two large trials to assess
both injectable and smokeable heroin treatment in Holland (van
den Brink et al.  2002). One reason for the lack of research is that
heroin is prohibited for use in the treatment of opiate dependence
in many countries, and pressure brought to bear from the
International Narcotics Control Board against countries wanting
to conduct research trials. Another is the cost of trials; the
recently approved Canadian trial has a budget of $CAN 8.1m
(Canadian Institutes of Health Research 2005). Currently the
UK’s National Treatment Agency is planning a controlled trial of
injectable heroin across three sites. However, in contrast to recent
research in Switzerland and the Netherlands, this is not expected
to include smokable heroin.
“The evidence regarding heroin prescribing has recently been
comprehensively reviewed by Stimson and Metrebian (2003). The
main findings of the review are that:
• Prescribing heroin is practical in specialist treatment
settings
• The drug is as safe for patients as comparable treatments
with injectable drugs;
• Prescribing is safe for clinic staff;
• Prescribing heroin does not pose problems for the
Community;
• Heroin is not diverted to the illicit market;
• Patients can be maintained on a stable dose of heroin;
• It is uncertain whether is attracts more drug users into
Treatment;
• It does not appear to discourage patients from accepting
oral methadone treatment;
• Patients are retained in treatment as well as or better than
Methadone;
• Illicit use of heroin and other drugs decreases;
• Health improves;
• Social functioning improves;
• Patients commit less crime than before being prescribed
Heroin;
• Patients tend not to switch to methadone or oral routes
of Administration;
• It is not clear who does best on the treatment;
• At current levels of prescribing heroin probably does not
undercut the illicit markets in drugs and reduce drug
scenes;
• Prescribing heroin is more expensive that methadone but
is nevertheless cost effective; and,
• It is uncertain if heroin prescribing is more cost-effective
than methadone.
Adoption and implementation
Beyond the UK, Switzerland and the Netherlands, scientific trials
are planned or are taking place in Germany, France, Belgium,
Spain, and Canada. In 1992 Australia undertook research studies
on the feasibility of prescribing heroin but the proposed trial was
not sanctioned by the Australian government. Evidence suggests
that diplomatic pressure from the United States and the
International Narcotics Control Board helped stifle further
moves to implement trials in the late 1990s (Bewley-Taylor 2001:
216; Hamilton 2001: 114-5).
Summary
Despite the findings of research so far, the evidence base for
heroin prescribing is weak; with few studies, and only four with
control groups. Therefore the findings concerning the effect of
heroin prescribing should be treated cautiously. That said, it
appears that there are health and social gains when this treatment
is offered to long term injectors and smokers for whom other
treatments have failed. The existing evidence suggests that there
should be a cautious expansion of this form of treatment
accompanied by further evaluation.
Information, Education and
Communication (IEC), Outreach and
Motivational Enhancement
Background
A variety of approaches can be used to complement or augment
the work of NSPs and drug dependence treatment to prevent the
transmission of blood-borne infections or overdose and
otherwise promote health. These include targeted or mass media
‘Information, Education and Communication’ (IEC)
programmes and community-based outreach. The aim of such
programmes is to inform, enable and persuade populations who
are at risk to adopt self-protection behaviours. In some cases,
programmes draw directly on widely-used motivational
enhancement techniques.
The World Health Organisation (1998b) describes information,
education and communication (IEC) approaches as an essential
component of the response to HIV infection among injecting
drug users. IEC principles are also employed to address many
other forms of drug related harm, such as the risk of heatstroke
incurred by ecstasy users, or overdose among opiate users.
Materials such as leaflets, videos and web-based materials are
produced and used extensively by organisations specialising in
harm reduction work with drug users and are widely used to
complement other programmes such as NSPs and opioid
maintenance.
According to the WHO, UNAIDS and UNODC (2004d),
community-based outreach “aims to contact drug users in the
communities where they live, use drugs and gather, and to
provide them with information and the means to reduce the risks
of acquiring HIV infection related to the sharing of injecting
equipment and sexual contact. Outreach is also intended to
prevent other health and social consequences of drug use”.
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Through face-to-face contact with IDUs, programmes provide
sterile needles and syringes, literature about HIV risk reduction,
distribute condoms and bleach for disinfection of needles and
syringes (especially where NSPs are not operating), promote
teaching and modelling of HIV risk reduction by network
leaders, referral to services, improve access to risk assessment and
HIV testing, provide counselling and support community
organising.
IEC and outreach can each be concerned with enhancing people’s
motivation to change and ‘motivational training’ is central to the
World Health Organisation’s (1998b) conception of IEC
approaches to preventing HIV infection among drug users. Many
practitioners working with drug and alcohol users draw directly
on motivational interviewing, which has been defined as “a
client-centred, directive method for enhancing intrinsic
motivation to change by exploring and resolving ambivalence”
(Miller and Rollnick 2002).
Clinical and cost effectiveness
Despite their widespread use, there is relatively little research on
the effectiveness of IEC programmes. This may partially be
explained because they are generally integrated into wider
programmes, which are evaluated in their entirety, and from
which it would be difficult to disaggregate their effects (For
example, see Coyle et al. 1999). This is especially the case within
resource-constrained countries and countries in transition.
Although mass media approaches can be effective at reaching
marginalised groups, messages will not always be socially
acceptable to all communities and, language differences, illiteracy
and the diversity of drug using practices also constrain what may
be possible (Aggleton et al. in press). Importantly, Aggleton et al.
draw attention to a largely unrecognised aspect of IEC
programmes concluding that:
…more explicit recognition should be given to the role of IEC in
preparing the way for a range of programmes and interventions
that are known to work in relation to HIV prevention.  These
can help policy-makers, opinion formers, religious leaders and
community members develop a more realistic understanding of
IDUs and their needs.  They can also result in the overall
destigmatization of injecting drug use, which is an important pre-
requisite for service use.
The evidence base for community-based outreach programmes is
rather better developed. A review of 36 publications examined
the following outcomes (proportion of studies reporting positive
findings are shown in brackets): cessation of injecting (10/11),
reduced injecting frequency (17/18), stopped/reduced reuse of
needles and syringes (16/20), reuse of other paraphernalia for
injecting (8/12), reduction/cessation of crack use (7/7), needle
disinfection (10/16), drug treatment entry (6/7) and increased
condom use/reduction in unprotected sex (16/17) (Coyle et al
1999). A recent commissioned review by the World Health
Organisation (2004f) concludes that:
Outreach is an effective strategy for reaching hard-to-reach,
hidden populations of IDUs and provides the means for enabling
IDUs to reduce their risk behaviours; a significant proportion of
IDUs receiving outreach based interventions reduce their risk
behaviours drug using, needle and sexual practices and increase
their protective behaviours; changes in behaviours have been
found to be associated with lower rates of HIV infection.
Although motivational enhancement approaches may be seen as
integral to IEC and outreach approaches, several studies have
explicitly drawn on motivational enhancement techniques to
promote behaviour change. Two Australian papers have reported
results from an adaptation of motivational interviewing in
changing injecting and sexual risk behaviour (Baker et al. 1993;
Baker et al. 1994). The results from these studies are inconclusive
as both the treatment and control groups showed reduced risk
behaviour. Resnicow et al. (2002) review three studies that have
aimed to increase HIV sexual risk reduction strategies amongst
women using motivational interviewing principles. These studies
indicate some behaviour changes consistent with reducing HIV
sexual risk compared to control groups.
Only a small number of studies have looked at the cost-
effectiveness of IEC approaches and a recent review concludes
that “more research is needed to investigate the cost-effectiveness
of IEC activities both on their own and as part of structured HIV
prevention programmes (Aggleton et al. in press).
Adoption and implementation
Aggleton and colleagues (in press) give a number of case studies
of IEC approaches from within Ukraine, Australia, Argentina
and the UK, which include examples aimed at women, ethnic
minorities and drug users in prison. It is unclear how widely or
well these have been adopted though the need to fine tune
programmes to local needs almost certainly means that there is
considerable potential for them to be used more effectively.
Regarding community-based outreach, the WHO (2004f:5)
identify a large discrepancy between need and provision
concluding that “despite evidence of the effectiveness of
community-based outreach from 15 years of evaluation studies, a
huge gap exists in most countries between the number of IDUs
who want or could benefit from outreach services and the
number of IDUs who actually receive them”. Community-based
outreach programmes are quite widely implemented in the USA,
where much of the theoretical development has also taken place.
The WHO identifies examples also exist across central and
eastern Europe, the newly independent states, western Europe,
Oceania, and Latin America. With some exceptions coverage is
poorer in much of Asia and no outreach programmes for IDUs
were identified in Africa.
Summary
The evidence surrounding IEC approaches is generally weak but
they appear to be a potentially useful element within harm
reduction programmes and their value in preparing the ground
for other HIV prevention interventions seems under-recognised.
There is a clear case for developing and evaluating IEC
approaches in ways that should be tailored to local circumstances
and that improves the evidence base. The evidence surrounding
community-based outreach is better developed and the case for
expanding them is more clear cut as provision is patchy, at best,
in most regions of the world.
Interventions to reduce overdose and
poisoning
Background
A diverse range of activities to reduce drug-related deaths have
been developed and adopted to differing degrees: for example see
the national commissioning guidance within the UK (NTA 2004).
In many cases these have not yet been subject to extensive
research; nevertheless, their growing adoption within responses
to overdose suggests that these are important to consider and
that, in time, it will be important to appraise any contribution
they might make. Some of the more prominent examples are
summarised within this section.
10 Report 4
Whereas the production of regulated drugs has to adhere to strict
production standards with regular inspection of manufacturing
and distribution facilities; illegal drugs are not subject to such
controls. Harms can arise from contamination, adulteration and
dosing errors associated with unexpectedly high purity drugs.
Fatalities have arisen in connection with MPTP contaminated
heroin, scopolamine poisoning, PMA within ‘ecstasy’ tablets and
clostridium infections such as botulism. Harm reduction
responses to these hazards include early warning systems and pill
testing.
An expanding range of interventions has also developed in
response to the growing recognition that drug users are
frequently present and attempt to intervene and save lives when
someone overdoses. These include: campaigns to encourage drug
users to call emergency services; training and information
concerning overdose prevention and its management e.g. training
in the recovery position and CPR: and, programmes to provide
the opioid antagonist naloxone to drug users and others around
them for use in emergencies.
Clinical and cost-effectiveness
A wide variety of early warning systems exist (Griffiths et al.
2000). Increasingly these inform targeted information campaigns
through governmental and other health and social care agencies
to alert drug users to periodic hazards due to contaminated or
adulterated drugs, such as those of the US Center for Disease
Control (1984) regarding MPTP contaminated heroin and the
European Infection Warning System (Christie 2000), which
issued alerts concerning clostridium infections. The growing
focus on new synthetic drugs through initiatives such as the
European Early Warning System on New Synthetic Drugs
(EMCDDA 2002a) enables alerts to be issued regarding
contaminated ‘ecstasy’ pills such those found to contain PMA.
The impact of such systems is largely unevaluated and there is a
need to further investigate how they can be optimised and
relevant information best be communicated to the populations at
risk.
Pill testing is increasingly used in clubs and festivals within which
‘ecstasy’ is used. It is one way in which early warning systems
can alert drug users to batches of high strength or contaminated
pills. Services providing pill testing are also a way by which
information about hazardous substances can potentially be
disseminated to drug users.
The evidence base surrounding pill testing is not very well
developed and at present it is difficult to appraise its overall
impact on health. It appears to have merits for facilitating contact
with ecstasy users and gathering and providing information. The
European Monitoring Centre on Drugs and Drug Addiction
(EMCDDA 2001) has concluded that currently:
• Pill testing interventions are important measures to enter
into contact with hard to reach populations and to raise
their interest in preventive and harm reduction messages.
• On-site pill testing interventions should closely be
linked to information provision with preventive and
“safer use” messages, through a wide range of
information supports.
• Due to the lack and difficulties of evaluation, on the one
hand there is still no strict scientific proof for the
protective impact of on-site pill-testing interventions but
on the other hand, there is also no scientific evidence to
conclude that such interventions rather promote drug
use or might be used by dealers for marketing purposes.
• There is a need for more research and evaluation studies
on the whole range of effects of on-site pill-testing
interventions. This appears to be a prerequisite in policy-
making when completing the range of strategies to
respond to drug issues in recreational settings.
A growing number of countries are developing campaigns to
encourage drug users to call emergency services and are
providing information programmes concerning overdose
prevention and its management e.g. training in the recovery
position and CPR (for example, see NTA 2004). The evidence
surrounding their effectiveness is largely restricted to local
process evaluations. Nevertheless, these show promise and such
interventions can readily be linked in with other programmes
including NSPs and substitute prescribing, providing greater
effectiveness and value for money.
Pilot programmes involving the provision of naloxone to drug
users who receive training in its administration during
emergencies have documented its successful use to save lives
without adverse effects (Dettmer et al.  2001). It was estimated
that the drug costs for each life saved was in the range £330-£670.
Adoption and implementation
Early warning systems of different sorts exist in most developed
countries across North America, Europe and Oceania and pill
testing is available to some degree in various European countries
including the Netherlands, Austria, Belgium, Germany, Spain,
France and Switzerland; although it only comprises part of the
official drug policy in the Netherlands (EMCDDA 2001).
Despite the large number of overdose deaths annually, other
targeted programmes to reduce overdose deaths appear to be
provided patchily or on a pilot basis only. The difficulties in
describing the extent of drug overdose globally seem to be
mirrored in our limited understanding of the coverage of
specialist interventions targeting overdose (WHO 1998a).
Summary
Evidence is accumulating to show that early warning systems, pill
testing and, programmes both to prevent overdose and to
improve emergency responses can be effective. In most cases the
evidence is limited, often reflecting the relative newness of these
responses.  Nevertheless, the interventions summarised in this
section are important candidates for further research in order to
understand better how they may contribute to the reduction of
drug-related deaths.
Drug Consumption Rooms
Background
The evidence concerning Drug Consumption Rooms (DCRs) has
recently been reviewed as part of the Beckley Foundation’s own
programme of publications and should be consulted for a more
detailed review of the issues concerning their operation (Roberts
et al. 2004). DCRs have been defined as “protected places for the
hygienic consumption of pre-obtained drugs in a non-
judgemental environment and under the supervision of trained
staff” (Akzept 2000). They aim to reduce harm both for the drug
user and the wider community; enabling drug users to use drugs
more safely and hygienically and reducing public nuisance
associated with street drug use. Models of practice vary and they
are largely restricted to locations with high levels of public
injecting or open drug scenes. Most services are aimed at IDUs
but some target heroin or crack smokers.
11Report 4
Clinical and cost-effectiveness
Their evidence surrounding their impact has developed since
their introduction in the 1980s and been comprehensively
reviewed by the European Monitoring Centre for Drugs and
Drug Addiction (Hedrich 2004) and subsequently considered
within a briefing paper that comprises part of this series (Roberts
et al. 2004). These should be referred to for a fuller treatment of
the topic.
The evidence suggests that across the main expected health and
welfare outcomes DCRs:
• Can be effective in attracting marginalised or hard-to-
reach drug users including the homeless and commercial
sex workers and promoting more hygienic injecting;
• Reduce risk behaviours and enhance knowledge relating
to the transmission of HIV, HBV and HCV;
• Enable early intervention within potentially fatal
overdoses and other drug-related emergencies;
• Facilitate access and referral to treatment and social
welfare and social reintegration services.
Public order outcomes that have been found include reductions
in:
• reductions in public drug-taking and the effective
disruption of open drug scenes; and,
• Reduced levels of discarded needles, syringes and other
drug related litter.
It is worth noting that one particularly well-designed study
published since the EMCDDA and Beckley reports (Woods et al.
2004) has significantly strengthened the evidence concerning
DCRs’ beneficial impact on public order outcomes.
To date, most research has been focused on the underlying
effectiveness of DCRs and there has been less emphasis on cost-
effectiveness, which is likely to be greatly affected by the model
adopted. Whereas specialised services such as the Sydney
Medically Supervised Injecting Centre have quite high costs,
services that are integrated with other treatment provision (as
encountered in Switzerland, the Netherlands and Germany) have
lower direct costs.
Adoption and implementation
At present, DCRs are available in seven countries - Australia,
Germany, Switzerland, the Netherlands, Spain, Canada and, very
recently, Norway. Facilities have been planned within Portugal
and Luxembourg and have been contemplated, but rejected, in
Denmark (EMCDDA 2002b: 35).
Summary
There is good evidence that, when developed in consultation with
the wider community, a range of operational models for drug
consumption rooms is possible, and these can serve differing
populations and local needs. Injecting can be transferred to a
safer environment, simultaneously decreasing nuisance. DCRs
attract more marginalized and vulnerable drug users and there are
indications that they prevent overdose deaths and may reduce
risk behaviours for blood-borne viruses. Beyond this, they can
provide access to a range of drug treatment, health and social care
services. As yet, the cost-effectiveness of consumption rooms is
uncertain. Whilst they show some promise, further research is
required to clarify their overall impact and value for money.
IMPLEMENTING EFFECTIVE
INTERVENTIONS: PRIORITIES
FOR ACTION
A substantial accumulation of scientific research from different
regions of the world now underpins a range of interventions that
aim to reduce the most serious harms associated with drug use.
Among these, the evidence is strongest and most consistent with
regard to a) the capacity of needle and syringe programmes to
prevent HIV/AIDS and, b) the role of opioid substitution
treatment in reducing heroin use and its various risks. Beyond
scientific appraisals, the robustness of the evidence is also
reflected through international statements, declarations and
position papers, which draw attention to priorities for effective
intervention.
‘UN Statements on Harm Reduction - Shifting Emphasis’.
When working with people who inject drugs, it is important to focus on
harm reduction as well as rehabilitation…[and to] adopt a multi-
pronged approach including needle and syringe exchange…and
substitution pharmacotherapy.
Innovative Approaches to HIV Prevention, UNAIDS Best Practice
Collection, 2000:8.
The Board wishes to reiterate that drug injection rooms (or any other
similar outlets established in some developed countries) might even
facilitate drug abuse, are contrary to the international drug control
treaties and interfere with obligations of law enforcement authorities.
INCB Annual Report, 2002:70
…to promote drug use illicitly through the giving out of
needles…would, to me, amount to inciting people to abuse drugs, which
would be contrary to the provisions of the conventions.
 Dr. Philip O. Emafo, President of the International Narcotics Control
Board (INCB), 2002.
Available from http://www.unodc.org/unodc/newsletter_2002-12-
31_1_page004.html
Community-based outreach is one component of a comprehensive HIV
prevention model to prevent the further spread of HIV among IDUs.
Other components include access to clean needles and syringes [and] a
range of drug dependence treatment options…
Evidence for Action: Effectiveness of Community-Based Outreach in
Preventing HIV/AIDS Among Injection Drug Users, WHO, 2004f
The provision of access to sterile injection equipment for injecting drug
users and the encouragement of its use are essential components of
HIV/AIDS prevention programmes…
Evidence for Action on HIV/AIDS and Injecting Drug Use – Policy
Brief: Provision of Sterile Injecting Equipment to Reduce HIV
Transmission, WHO, UNAIDS, UNODC, 2004a
There is compelling evidence that increasing the availability and
utilization of sterile injecting equipment by IDUs reduces HIV
infection substantially…There is no convincing evidence of any major,
unintended negative consequences.
Effectiveness of Sterile Needle and Syringe Programming in Reducing
HIV/AIDS Among Injecting Drug Users, WHO 2004a.
The evidence obtained in more than 15 years of research and
evaluation…strongly indicates that outreach-based interventions are
effective in contacting out-of-treatment injecting drug users and
providing them with the means for effective behaviour change.
Evidence for Action on HIV/AIDS and Injecting Drug Use – Policy
Brief: Reduction of HIV Transmission Through Outreach, WHO,
UNAIDS UNODC, 2004.
We neither endorse needle exchange as a solution for drug abuse, nor
support public statements advocating such practices.
Letter from UNODC Executive Director Antonio Costa to US State
Department, November 2004.
Available from http://www.colombo-plan.org/www/images/pubs/pdf/
unodcnov2004.pdf
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In its Declaration of Commitment on HIV/AIDS in 2001, the
UN General Assembly affirmed the importance of providing
sterile injecting equipment and wider harm reduction efforts
related to drug use (paragraphs 23 and 52). The joint position
paper of the WHO, UNODC and UNAIDS on substitution
maintenance therapy for opioid dependence and HIV/AIDS
prevention describes it as “one of the most effective treatment
options for opioid dependence” that is effective for “reducing
heroin use, associated deaths, HIV risk behaviours and criminal
activity” and concludes that provision of substitution
maintenance therapy “should be considered as an important
treatment option in communities with a high prevalence of opioid
dependence” (2004c). These positions were endorsed and
elaborated within the Leadership statement on injecting drug use
and HIV/AIDS at the 15th International Conference on AIDS in
Bangkok In 2004: a statement that details a number of global
priorities for action (UNAIDS 2004).
Despite these endorsements, the availability of effective
interventions with a known ability to reduce drug related harm is
uneven. In particular, the populations of many countries with
developing or transitional economies and with significant levels
of opioid dependence do not have good access to treatments that
can enhance their health and well-being and prevent HIV/AIDS.
This section provides an overview of the main challenges that
hinder the adoption of these interventions and, by implication,
priorities for action.
The follow-up report (UNAIDS 2003) to the United Nations
General Assembly (UNGASS) special session on HIV/AIDS in
2001 identified generalised problems that contribute to low
coverage within services for IDUs across countries in Asia and
the Pacific (Bangladesh, China, Hong Kong, Indonesia, Malaysia,
Myanmar, Neal, Pakistan, Philippines, Singapore, Thailand, Viet
Nam), Latin America (Argentina and Brazil), Eastern Europe and
Central Asia (Belarus, Kazakhstan, Republic of Moldova,
Romania, Russian Federation, Ukraine) and the Middle East
(Iran). These include a lack of good information on programme
coverage and epidemiology along with: insufficient financial
resources; lack of human resources and technical capacity; stigma
and discrimination; and, poor information systems. Their
corresponding recommendations are that:
• “countries urgently need to ensure that a comprehensive
package of HIV-prevention services is implemented and
coverage expanded to guarantee access for all vulnerable
groups”;
• Increased political commitment and assertive political
leadership is urgently needed within Asia and the Pacific
and in Eastern Europe and Central Asia;
• Support is urgently required to enable countries to build
up institutional capacity; and,
• “the implementation and enforcement of measures to
eradicate HIV/AIDS related stigma and discrimination
are urgently needed”.
To fulfil the declaration’s future commitments it has been
estimated that a threefold increase in the annual funding for HIV/
AIDS programmes was needed by 2007 (UNAIDS 2003: 68-69,
78-80). Beyond these points that have widespread application it is
useful to consider issues that are specific to several different states
and regions.
In Central and Eastern Europe, Russia remains particularly
anomalous with her continued prohibition of the use of
methadone and buprenorphine. The significance of this legal
impediment to evidence-based practice is all the greater, given the
seriousness of the HIV/AIDS pandemic across the Russian
Federation and several of its neighbouring states. Otherwise,
problems across the region involve a generalised need to scale up
NSPs and prescribing services, which is made more difficult
because of the “negative image presented by the media…reflected
in the views of the general population and often the
professionals” (WHO 2004c:15). Legal revisions to the Russian
penal code in 2004 seem likely to have partially reversed a
recommendation of the State Drug Control committee that had
led to disinvestment in NSPs although there remains much
confusion about their legal status among practitioners and local
policy makers.
The problems identified by UNAIDS (2003) - insufficient
financial resources; lack of human resources and technical
capacity; stigma and discrimination; and, poor information
systems - are generally applicable across South-East Asia and the
Western Pacific. There is also substantial scepticism about the
efficacy of substitute prescribing programmes; with widely-held
views that such treatments are “too soft on addicts” along with
recognition of the importance of cultural sensitivity in the way
that programmes are developed (WHO 2002:16). Nevertheless,
there is a growing preparedness to pilot or scale up substitute
prescribing programmes and NSPs. Given its influence in the
region, China’s growing readiness to pilot and adapt NSP and
substitution programmes to address growing HIV prevalence is
an important step that may challenge this resistance.
Among the richer, industrialised countries that have significant
opiate dependence problems the USA seems unique in its level of
resistance to NSPs, with a continual Congressional ban on
Federal funding (Strathdee and Bastos 2003): a position that is in
contrast with the leadership the USA has shown in the
development of opioid substitution therapy. Consequently, NSP
provision is highly inconsistent and fails to achieve good
coverage across many states. At the national level, political
opposition to the funding of NSPs remains strong despite two
Consensus Statements from the National Institutes of Health
(NIH).
The 1997 statement on Interventions to Prevent HIV Risk
Behaviors concluded that:
Behavioral interventions to reduce risk for HIV/AIDS are
effective and should be disseminated widely. Legislative
restriction on needle exchange programs must be lifted because
such legislation constitutes a major barrier to realizing the
potential of a powerful approach and exposes millions of people
to unnecessary risk.
(NIH 1997)
The 2002 statement on Management of Hepatitis C
recommendations included:
Institute measures to reduce transmission of HCV among IDUs,
including providing access to sterile syringes through needle
exchange, physician prescription, and pharmacy sales; and
expanding the Nation’s capacity to provide treatment for
substance abuse. Physicians and pharmacists should be educated
to recognize that providing IDUs with access to sterile syringes
and education in safe injection practices may be lifesaving.
(NIH 2002)
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CONCLUSION
While the evidence base for the reduction of drug-related health
harms continues to emerge - particularly on the more
experimental approaches such as Heroin Prescribing or
Consumption Rooms, and delivery in developing countries -
there is now ample evidence that the core ‘Harm Reduction’
activities, when implemented in a timely and professional
manner, have proved their worth in averting large-scale
transmission of infections, and reducing death rates amongst drug
users. There are also encouraging indications that the accessible
provision of services such as needle exchange and substitute
prescribing is an effective way to make contact with a ‘hidden’
population of drug users, stabilise their behaviour, and encourage
them to take steps towards giving up their risky lifestyle.
However, concerns remain that the existence, and public
promotion, of these approaches create an atmosphere and
environment that encourages higher levels of injecting drug use.
We were not able to locate any evidence where such a link has
been identified – indeed, the consensus statement issued by the
WHO, UNAIDS and UNODC (2004a, 2004c) acknowledges
this point specifically. We are therefore concerned that the
resistance to these measures, at community and policy level, is
more due to ideological unease at being ‘soft’ on drug users,
rather than any objective appraisal of the evidence. The
resolution of these concerns is a matter for urgent attention in
those countries and regions currently facing widespread injecting
drug use – national governments and international agencies need
to agree effective responses to potential HIV epidemics in Central
and Eastern Europe, across Asia, the Middle East and Latin
America. Western European and North American countries need
to develop more effective responses to HIV/AIDS, Hepatitis
infection and overdose deaths. The temptation to avoid difficult
policy choices now will, according to our currently accumulated
knowledge, lead directly to significant avoidable loss of life, and
treatment and healthcare expenditures, in the future.
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